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Synthetic biology is capable of delivering new solutions to key challenges spanning the bioeconomy, both
nationally and internationally. Recognising this signiﬁcant potential and the associated need to facilitate
its translation and commercialisation the UK government commissioned the production of a national
Synthetic Biology Roadmap in 2011, and subsequently provided crucial support to assist its
implementation.
Critical infrastructural investments have been made, and important strides made towards the devel-
opment of an effectively connected community of practitioners and interest groups. A number of Syn-
thetic Biology Research Centres, DNA Synthesis Foundries, a Centre for Doctoral Training, and an
Innovation Knowledge Centre have been established, creating a nationally distributed and integrated
network of complementary facilities and expertise.
The UK Synthetic Biology Leadership Council published a UK Synthetic Biology Strategic Plan in 2016,
increasing focus on the processes of translation and commercialisation. Over 50 start-ups, SMEs and
larger companies are actively engaged in synthetic biology in the UK, and inward investments are
starting to ﬂow.
Together these initiatives provide an important foundation for stimulating innovation, actively
contributing to international research and development partnerships, and helping deliver useful beneﬁts
from synthetic biology in response to local and global needs and challenges.
Crown Copyright © 2016 Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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1.1. The emergence of synthetic biology
The sustainable manufacture of products, ranging from medi-
cines to materials, and from foodstuffs to ﬁne chemicals, is a critical
factor in supplying the present and future needs of society. Such
needs will continue to expand alongside rising global human
population, as its impact upon the environment and its demand
upon planetary resources continues to increase. Synthetic biology,
at the heart of a bio-industrial revolution, is beginning to provide
fresh options to address such needs, spanning feedstocks, processes
and products.
Manufacturing processes have continued to evolve over the
centuries. Chemical synthesis methods have delivered important
products ranging from aspirin to synthetic polymers and dyes in
the nineteenth century to fertilisers and synthetic rubber in the
early twentieth century. Gradually replacing coal tar and whale oil
by crude oil as the major feedstock during the later half of the
nineteenth century inspired the development of petrochemical
processes that supply a vast range of products we currently beneﬁt
from, spanning fuels to ﬁbres and small molecule drugs to food
ﬂavourings. Fermentation, the basis of bread and beer making for
thousands of years, advanced in the nineteenth century through
the development of additional microbial processes and the dis-
covery of the role of enzymes as biological catalysts with very
speciﬁc function. Important medicinal products have been extrac-
ted or semi-synthesized from plants and animals for centuries, but
since 1982, when the ﬁrst approved ‘biologic’ e ‘human’ insulin
produced using recombinant DNA e reached the market, an
increasing proportion of therapeutics are now being synthesized.
Signiﬁcant global challenges necessitate the development of
evenmore effectivemanufacturing solutionse for example, how to
produce fuels, foods and materials more sustainably? How to
continue improving human and animal health and wellbeing?
Synthetic biology delivers the capability to manufacture complex
molecules and smart biological systems that to date have been too
expensive, very difﬁcult - or impossible - to produce. The under-
pinning techniques being developed may enable radically new
functionalities to be incorporated, such as the incorporation of
‘smart switches’ into biosensors, or to produce more speciﬁc or
bespoke drugs and therapies. It can be applied, for example, to
support advances in regenerative medicine by providing moreprecise techniques for drug discovery, cell therapy and tissue repair
[1]; to engineer bacteria for human digestive and environmental
health [2]; to engineer new traits in plants to assist nitrogen ﬁxa-
tion or to produce natural products [3], or to design fermentation
processes that can deliver high value biopharmaceuticals at greater
scale and affordability.
By improving the productivity of bio-manufacturing processes,
synthetic biology can help generate more sustainable materials,
chemicals and energy. Prospects for the advancedmanufacturing of
larger-scale industrial chemicals are also increasing e industrial
production of 1,3 propanediol (PDO), lysine and 1,4 butanediol
(BDO) using engineered E. coli provide early demonstrations of
commercial viability [4]. It is generally recognised that the expe-
rience gained from developing such products e for example for
related product families such as terpenoids related to artemisinin
by Amyris [5] - combined with ongoing advances in available bio-
logical toolkits and improved industrial chassis (other than the
ubiquitous workhorses E. coli and S. cerevisiae) will continue to
reduce development times and costs and hence enhance prospects
for future industrial uptake.
Noting certain parallels with the development of the micro-
electronics industry through the second half of the 20th century, it
is also possible to envisage these innovative developments her-
alding in new generations of biological computers [6], information
archiving systems [7] and in decades to come many other appli-
cations as yet unimagined.
Whatever the envisaged application, by applying core design
and engineering principles of characterisation, standardisation and
modularisation to biological systems within a core build-test-
analyse-learn cycle, synthetic biology can increase predictability
and development speed, and reduce costs. Solutions can be more
robust and compete effectively with more established processes, or
introduce new functionalities previously too difﬁcult or expensive
to consider. The development of better, faster, easier toolkits is itself
a signiﬁcant aspect of synthetic biology. As the ﬁeld becomes more
automated and predictable, developers will be able to focus more
on the design of outcomes than on the implementation of labora-
tory processes themselves.
It is in reﬂection of such prospects for the delivery of signiﬁcant
beneﬁts to health, economy and security that the UK has placed
particular emphasis on the pursuit of research and development of
synthetic biology, framed within the broader scope of stakeholder
interests as outlined within the original UK Synthetic Biology
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1.2. Context - evolution of revolution?
Assessing the potential future signiﬁcance of any innovative
technology is necessarily beset with uncertainty, and the history of
technological development is littered with lists of unfulﬁlled ex-
pectations. However, synthetic biology is not deﬁned narrowly in
terms of any speciﬁc outcome, but instead describes a platform
technology with multiple possible applications, some of which are
already delivering useful results, whilst others may take much
longer or indeed never materialise. It provides core capabilities to
accelerate and commercialise ideas within a much broader context
of developments in the biological and life sciences that are evolving
rapidly and to which the term ‘revolutionary’ is increasingly being
applied. Such developments are likely to expand the opportunity
space rather than constrain the possible options.
A reasonable argument can be made to support the view that a
scientiﬁc (‘Kuhnian’) revolution in genomics and the life sciences
has been taking place since the turn of the 21st century [9]. The
foundations for this extraordinary acceleration in progress were set
in the middle of the last century, notably with the discovery in 1953
of the structure of DNA by Crick and Watson in Cambridge. As
Sidney Brenner, amongst the very earliest students to recognize the
signiﬁcance of Crick and Watson's discovery, and himself subse-
quently awarded a Nobel prize for his own major contributions to
the ﬁeld, stated upon the 60th anniversary of the discovery that “…
the real paradigm shift stemmed from the fact that it introduced of
the idea of information and its physical embodiment in DNA se-
quences of four different bases” [10]. But it took a further half a
century before the investment in developing high-throughput
instrumentation and associated software capable of extracting
the complete structure of the human genome emerged from the
Human Genome Project (HGP) 1992e2000 [11]. Within a decade of
the completion of the HGP, a succession of further instrumental
developments has transformed sequencing to a widely affordable
and broadly applicable technique, enabling an explosion in gene-
level data generation. This has coincided with a parallel ‘revolu-
tion’ in information technologies e hardware and software -
capable of handling and analysing such enormous amounts of data,
enabling understanding of the relationship between biological
form and function at the gene level to be progressed [12]. Such
developments continue to proceed alongside a raft of rapid and
complementary scientiﬁc and technological advances and discov-
eries e including micro-ﬂuidics, increasingly sensitive and rapid
analytical techniques and increasingly precise gene-editing tech-
niques such as CRISPR-Cas9 [13,14] e collectively contributing to-
wards increasing predictability and cost reduction, transforming
prospects for the widespread delivery of commercially viable
solutions.
The convergence of biological and engineering concepts as a
basis of a new technological revolution was mooted in the report
‘Synthetic Biology’ by the Royal Academy of Engineering (RAE) in
2009 [15]. It has subsequently been proposed by Prof. Schwab of the
World Economic Forum [16] that the broader fusion of physical,
digital and biological breakthroughs heralds the dawn of a ‘Fourth
Industrial Revolution’. The economic consequences may also be
associated with the growing ‘Knowledge Economy’ anticipated by
Deming as long ago as 1993 [17].
In summary, it remains to be determined whether future his-
torians will view current progress in such broad terms, but there is
no doubt that the term ‘scientiﬁc revolution’ is not misplaced with
respect to the digitization of biology, the development of toolkits
that enable rapid and effective translation, and the opportunities
that are opening up as a result. If in scientiﬁc terms the 19thcentury is considered to have been the age of chemistry, and the
20th century the age of physics, only timee and persistent research
effort - will determinewhether the 21st century will deliver the age
of biology, with synthetic biology at its leading edge.
1.3. Conceptualisation of synthetic biology
A strong legacy of academic research achievements set the
foundations for the development of synthetic biology in the UK.
Examples highlighted in the 2012 Roadmap include:
“The discovery by James Watson and Francis Crick of the
structure of DNA in 1953 and seminal follow up work by Crick in
1961 which cracked the DNA-to-protein code, laid the foundations
onwhich all Synthetic Biology designs now rely. UK expertise led to
the discovery of reverse transcriptase (now an indispensible part of
molecular biology) and the development by Frederick Sanger in
1977 of a vastly improved sequencing method. This led to huge
scientiﬁc advances including the Human Genome Project.
In the 1990s Professor Shankar Balasubramanian and Professor
David Klenerman from the University of Cambridge invented Sol-
exa sequencing: an ultrafast method for sequencing DNA which
improved cost and speed by 1000 to 10,000 fold on previous
technologies. Solexa was sold to Illumina for $600 M in 2007 and is
the global market leader in next generation sequencing. This
expertise has continued to the present day.
Oxford Nanopore Technology (ONT) has developed a new
sequencing technology based on fundamental research from the
University of Oxford, which works by running a strand of DNA
through a tiny hole called a nanopore. Developments such as these
are leading to a point where DNA can be sequenced in real-time
opening up exciting new possibilities for medicine and biotech-
nology [18].
The principles of synthetic biology began to emerge in the UK
around the time the Human Genome Project was being published
in 2002, funding for networks in synthetic biology awarded from
2007, and in 2009 the Imperial College Centre for Synthetic Biology
CSynBi was established. From the outset, the value of collaborative
working between research groups across the relevant physical and
social sciences was fully recognised and formulated through the
formation of the Flowers Consortium in 2010 comprising groups
from Imperial College, Kings College, the London School of Eco-
nomics (LSE), Cambridge University and Newcastle University [19].
The Flowers Consortium set to work on the cohesive development
of platform technologies and the integration of tools and meth-
odologies critical to the ability to undertake systematic design. This
included the deﬁnition and implementation of key emergent
metrology concepts and standards (DICOM-SB and SBOL) and their
integration into an enabling IT infrastructure (SynBIS) e built to
enable efﬁcient information exchange and extraction. Reﬂecting
the rapid uptake of interest in the ﬁeld, stimulated by support from
the UK research councils, synthetic biology research, or research
closely related, was also starting to being carried out in numerous
other universities across the UK.
Such background developments set the stage for the UK syn-
thetic biology initiative e how to translate this emerging knowl-
edge into beneﬁts for society and the economy? Synthetic biology
provides a mechanism to address this challenge by taking foun-
dational research from a range of ﬁelds (for example, biochemistry,
systems engineering, molecular biology, plant sciences, chemical
engineering, informatics, microbiology) and integrates and builds
upon these ﬁndings through the application of engineering design
principles [20]. The resulting discipline may be described as a
‘translational ﬁeld’ e helping to extract important beneﬁts from
new insights. Synthetic biology sets out to utilise the inherently
modular nature of biological systems as a basis for deﬁning discrete
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practice the development of a robust system will emerge from a
design cycle that manages and accelerates the interplay between
experiment and theory, and should become more rapid as knowl-
edge continues to unfold. To become an effective basis for design
andmanufacturing, the formalisation of this approach also requires
an increasing degree of new standardisation and interfacing with
established standards (e.g. manufacturing standards).
The incorporation and adaptation of engineering principles and
techniques, to help translate such opportunities into reliable and
robust systems that can deliver beneﬁts as intended, is an integral
and vital element of synthetic biology. Rationalising the complex
relationship between structure and function permits higher levels
of abstraction to be applied, further aiding design speed, consis-
tency and predictability.
The domain of synthetic biology emerging from this perspective
is captured schematically in Fig. 1. The increasing ability to predict
functional behaviors via information management at the genomic
level combined with the application of engineering-type method-
ologies e in effect shifting the operational foundation from pre-
dominantly analogue to digital - leads towards the emergence of a
‘biodesign’ capability as described below in Section 4.
The principles of Synthetic Biology and a working deﬁnition
were captured in a report by The Royal Academy of Engineering in
2009 [21], coinciding with the establishment of the UK's ﬁrst
dedicated Synthetic Biology Department ‘CSynBI’ at Imperial Col-
lege. A valuable working deﬁnition of Synthetic Biology, as
expressed in The Royal Academy of Engineering report is: ‘the
design and engineering of biologically based parts, novel devices
and systems as a well as the redesign of existing, natural biological
systems’. Although the ﬁeld itself has progressed substantially over
the past seven years, and whilst many alternative deﬁnitions have
been proposed by others over this period, this working deﬁnition
has remained relevant and useful, and adopted for consistency in
both the 2012 UK Roadmap [22] and the subsequent 2016 UKFig. 1. Schematic illustration of the emergence of the synthetic biology domain via the conﬂ
engineering principles.Strategic Plan [23].
As noted, synthetic biology has deﬁed the formation of an
internationally accepted deﬁnition, not least because it reﬂects the
convolution of several different disciplines, and represents a
constantly advancing frontier of scientiﬁc knowledge. Its impor-
tance derives from the innovative fusion of scientiﬁc and engi-
neering sources into a practical toolkit that facilitates the
translation of understanding into the development of practical
applications. We have found that our working deﬁnition used
above is fully adequate to capture the critical elements, and has
passed the test of time for this purpose over the seven years since it
was ﬁrst formulated. It is likely that attempts to be more precise
will fail to capture the full scope or be rapidly rendered obsolete as
new insights and advances continue to enhance the depth and
breadth of knowledge, and steadily shift the frontiers of research.
A consequence of this shifting focus is that not all potentially
relevant research in the world is described as synthetic biology
whilst other studies may use the synthetic biology descriptor but,
in fact, have only limited connection to themain technological core.
To explore this, an analysis of worldwide scientiﬁc publications and
IP in the domain of synthetic biology was carried out in 2011 by
Oldham [24]. This applied an ontological approach to map the
world's scientiﬁc literature through the prevalence of terms
commonly used in synthetic biology papers, irrespective of the use
of the term synthetic biology itself. The study concluded that most
synthetic biology-related publications and IP ﬁlings were in the US,
with the UK second. The combined total of the whole of Europe
publications in synthetic-biology-related research was comparable
to the US. There was evidence of potentially related research ac-
tivities in more than 40 countries and 500 funding agencies
worldwide, illustrating the breadth of interest and perceived rele-
vance of the ﬁeld in a broad range of contexts.
As the underlying frontier of knowledge continues to advance,
enabling attention to focus on translation and commercialisation, it
is reasonable to expect that synthetic biology will persist as theuence of advancing biological and informational technologies and the incorporation of
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predictable and precise techniques to be applied to ever more
challenging issues, but that their practical commercial application
will in many cases require the additional combination of numerous
other techniques separately relevant to the speciﬁc ﬁeld of
application.
As an important evolutionary step along the path towards
increasing application, it is clear that the underlying techniques of
synthetic biology are becoming ‘higher level’ (i.e. offering a simpler
coding system that is separated from the details of the operating
systems and are therefore easier for humans to understand). The
development and adoption of ‘higher-level’ languages to instruct
the required operations will start making the technology accessible
to a broader range of non-specialists who can then focus more on
the intended outcomes than on the mechanics of the underlying
build-test-analyse processes. This gradual shift in focus towards
‘Biodesign’ is already becoming a reality for simpler systems, whilst
remaining a signiﬁcant future target for more complex systems
[25].
1.4. Commercialisation e from roadmap to policy
In 2011 the UK government commissioned a review of signiﬁ-
cant technological advances, strengths and opportunities within
the UK emerging from its academic base. This was led by the
Technology Strategy Board (subsequently renamed InnovateUK).
The objective was the development of a policy that would better
address the so-called ‘valley of death’ between scientiﬁc discoveries
and commercial development, and the selection of a small number
of R&D-intensive ‘general purpose’ technologies with signiﬁcant
implications, around which to focus such a policy [26]. In the study
it was recognised that the UK possesses considerable breadth and
excellence of R&D expertise. Synthetic biology was just one of 170
candidate technologies initially screened during this study. That
synthetic biology was eventually selected as one of the ‘Eight Great
Technologies’ arising from this exercise can be largely attributed to
the combination of extensive legacy in related world-class research
and biotechnology commercialisation, the rapid expansion of R&D
interest speciﬁcally in synthetic biology across the UK that had
already taken place, and the prospects for substantial growth in
relevant product and service markets [27].
Recent data and market analyses support the expectation of
rapid market sector growth. For example, biotechnology as a sector
is growing substantially faster than GDP as a whole in leading
markets. Estimates for the US by Carlson (deﬁning the biotech-
nology sector in its broadest sense to encompass biologics/bio-
pharmaceuticals, GM crops and industrial biotechnology) suggest
annual growth exceeding 10% over the past decade, with revenues
already exceeding 2% GDP by 2012 [28]. The global biologics market
-including monoclonal antibodies, therapeutic proteins, and vac-
cines - is growing at a compound annual rate exceeding 10% and
expected to grow to £387bn by 2019 [29]. It is estimated that bio-
based chemicals now make up more than 10% of the US chem-
icals market [30], with projections for global synthetic biology
markets for chemicals to grow to $11bn by 2016 [31] delivering an
economic impact of at least $100bn by 2025 [32]. A study by Allied
Market Research issued in 2014 predicted a global market for
synthetic biology of around $38bn by 2020, growing at a CAGR of
44% during the forecast period 2013e2020 [33]. Although
comparative analysis suffers from an inherent lack of consistency in
the use of terms such as ‘biotechnology’, and future projections
must necessarily be treated with caution, a consistent pattern
emerges - of relative and substantial growth to date and anticipated
in future for biobased economies, to which synthetic biology is
expected to make an increasingly important innovativecontribution.
The global signiﬁcance of such developments had already been
recognised and addressed in a ground-breaking series of interna-
tional meetings convened under the auspices of the six academies -
the United Kingdom's Royal Society and Royal Academy of Engi-
neering, the United States' National Academy of Sciences and Na-
tional Academy of Engineering, and the Chinese Academy of
Science and Chinese Academy of Engineering - between 2010 and
2011 [34]. This series of meetings not only addressed issues directly
related to synthetic biology, but could be considered to have paved
the way for a new approach to engagement on emerging technol-
ogies. Of particular signiﬁcance was that the series of meetings
actively took note of the importance of globalisation and the
internationalisation of science e thus engaging as equal parties the
US, UK, and China and inviting participation in the meeting from
individuals around the world. It also actively took note of the
critical need to engage expertise outside of the life sciences/engi-
neering community in fostering an emerging technology e thus
engaging with ethicists, social scientists, policymakers, legal
scholars, and regulators.
The linkage of synthetic biology research to signiﬁcant com-
mercial strengths in the UK was also recognised. For example, it
was noted that the UK has one of the most dynamic and innovative
healthcare industries in the world, comprising around 600 com-
panies and employing some 67,000 people [35]. It has developed
over 20% of the world's top 100 selling medicines (second only to
the US) - more than the rest of Europe combined. Every one of the
top 10 pharmaceutical companies in theworld has a presence in the
UK. GSK [36] had recently committed an investment of more than
£500 m across its manufacturing sites in the UK, to increase pro-
duction of key active ingredients for its pharmaceutical products
and vaccines. Together with AstraZeneca, these two companies
alone have reported a combined turnover of £42bn (approx. 9% of
the global market). A report by the BIA in 2016 also noted the
importance of smaller companies to the pharmaceutical sector in
the UK e a R&D powerhouse with 585 pipeline projects in devel-
opment including the highest number of phase 3 projects, and
attractingmore than a third of all venture capital funding, in Europe
[37]. This provides a signiﬁcant channel to market for potential
biotech applications of synthetic biology.
This, combined with signiﬁcant strengths in the chemical and
petrochemical industries, clinical and health sciences, advanced
engineering, manufacturing and design, further supported the de-
cision to shortlist synthetic biology for inclusion as one of the ‘Eight
Great Technologies’ policy.
A feature of synthetic biology distinguishing it from the other
‘Eight Great Technologies’ as selected in 2012 was its relative ‘in-
fancy’ as an established sector - having only emerged as a new
concept during the previous decade. This is not only evident from
the aforementioned discussion regarding a deﬁnition, but at the
time there were very few worked examples of practical applica-
tions approaching market deploymente the development of syn-
thetic artemesinin and Artemisinin-based Combination Therapies
by the US company Amyris being a notable example at the time
[38]. On the other hand by addressing the challenges and oppor-
tunities at such an early stage of its development provided a
particularly valuable opportunity to map out an entire framework
for the development of the sector without preconceptions. The
main challenges faced by the Roadmap Coordination group
included issues such as: What is our Vision? How to translate this
rapidly emerging body of knowledge and capacity into a form in
which the anticipated beneﬁts could be developed? How could this
lead to an entire new bio-based industry within the UK?
On the basis that scientiﬁc and technological progress provides
the opportunity to deliver important beneﬁts to society, and given
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that could emerge it was clear that processes for discovering and
responding to the views of the public, or more strictly of the many
‘publics’ should be built in from the onset. A Public Dialogue [39]
was commissioned and the results analysed and considered
before any decision was made to prepare a Synthetic Biology
Roadmap, and so that its ﬁndings could inform the Roadmap
process.
In November 2011, the UK government requested the formation
of a Synthetic Biology Roadmap Coordination Group to review and
map out the opportunity in more detail. The group was set up to
operate in an independent capacity (advising government, not
implementing a pre-deﬁned policy), chaired, as proposed in the
Policy, by an industrialist with experience in the commercialisation
of ideas from research. The Roadmap Coordination Group
comprised representatives from industry, academia (universities
and higher education institutes spanning physical and social sci-
ences) and research funding bodies, together with observers from
relevant UK government departments (a full list of members is
included in Roadmap and also in the acknowledgements section of
this report).
The Coordination Group applied a variety of processes to stim-
ulate and collate material for consideration in the Roadmap,
including number of workshops at which the views of a broad
range of stakeholder groups e academic, industrial, social - were
enlisted. An intensive series of discussion meetings convened over
several months subsequently drew out the broad themes and main
recommendations. The Roadmap was completed and presented to
the UK Government in July 2012. As noted in the document, the
Roadmap reﬂected ideas from a wide range of sources but did not
purport to represent the totality of views existing within the UK
including within the group itself. Nevertheless, it permitted an
internally consistent approach to bemapped out that enabled some
immediate recommendations to be made. This led to the ﬁrst steps
in what was recognised could become a long-term programme of
development. It was also recognised that the precise trajectory
would undoubtedly adjust over time in response to new knowledge
and experience, and that a subsequent document or documents
would be required in due course as the focus of effort would shift
from the research environment towards one in which application
development and industrialisation would play a more signiﬁcant
role.
2. The 2012 UK Synthetic Biology Roadmap
The UK roadmap is not a conventional project plan. It does not
have a speciﬁc end-point set in time, such as ‘putting a man on the
moon’. Instead it sets out a framework that will facilitate the efﬁ-
cient development, evaluation and delivery of valuable options
spanning a wide range of possible application areas. This frame-
work encompasses a vision, value system, mechanism to promote
underpinning technological development e emphasising the
importance of systematic biodesign and industrial translation - and
a schematic multi-decade timeline to deliver useful applications
and beneﬁts.
A unifying theme may be envisaged in terms of a technological
‘pipeline’ through which ideas are developed, scaled and deployed
as needed. The efﬁciency with which innovations ﬂow from labo-
ratory to market relies on a wide range of factors, including the
operating environment and market readiness, embracing cultural
values and effective governance systems relevant to each type of
application. The availability of expertise and facilities, the regula-
tory environment, the ultimate value of the ﬁnal product or service,
all play a role. It recognises that certain enabling technologies and
useful applications could emerge in the near future whilst ongoingresearch will continue to inspire new opportunities and applica-
tions for many years to come. Given the rapidity of development,
the system must also be agile and responsive to new opportunities
and insights as they arise. The resulting need is for an integrated
matrix of parallel activities supported by a multi-year funding
commitment. The roadmap outlines a set of principles and in-
frastructures to support this system.
Our approach seeks to reconcile the concept of ‘vertical inte-
gration’ as may be delivered within an a fully integrated private
corporation with the recognition that critical decisions along the
pipeline within an open-ended national system will generally be
made by different public and private entities. Productivity of the
system as a whole will be greatest when avoidable delays at in-
terfaces between the various phases are minimised, and the pipe-
line is supplied with sufﬁcient ideas at the front-end, or effectively
linked to complementary ideas as it ﬂows along, to ensure the
outputs satisfy market requirements in an affordable and timely
manner. Mapping this process and identifying the critical success
factors and structural needs speciﬁc to the UK is the primary
objective of the Roadmap, consistent with the principles set out in
‘The Eight Great Technologies’ policy document, launched by the
then Minister for Science and Innovation, The Rt. Hon David Wil-
letts, in January 2013, which had the express objective of gener-
ating more effective links between emerging academic research
and the processes of commercialisation and industrialisation.
The UK Synthetic Biology Roadmap Coordination Group iden-
tiﬁed a package of measures to support and develop the UK-wide
research and industrial communities by enhancing the availability
of essential resources and information. These were summarized
under ﬁve main recommendations as listed below. Taken together,
they help shape the operating environment in which synthetic
biology ideas and applications may ﬂourish and deliver intended
beneﬁts. This package of recommendations was supported in full by
the UK government in 2012.
2.1. Invest in a network of multi-disciplinary centres to establish an
outstanding UK synthetic biology resource
Common themes running through the Roadmap were to facili-
tate communications and learning, and to generate a network of
experts across disciplines with customers, public and private in-
terest groups. Key to achieving this was to provide better access to
cutting edge resources for both academic community and industry.
A multi-disciplinary synthetic biology centre had already been
established within the UK in 2009 (CSynBI at Imperial College), and
it was proposed to establish a number of additional centres, to
boost the national research capacity and diversify our expertise,
stimulating innovation and facilitating the interfaces with industry
and other key stakeholders.
Under the ‘Synthetic Biology for Growth’ programme, two
annual competitions for new centres of multidisciplinary synthetic
biology research excellence were held in 2013 and 2014, and three
new ‘Synthetic Biology Research Centres (SBRCs)’ were awarded on
each occasion, each with ﬁve-year funding commitments. Together
with the original CSynBI centre at Imperial this has generated a set
of seven major multidisciplinary hubs across the UK.
Each SBRC has its own cooperative network of research groups
and smaller centres, collectively comprising more than 30 univer-
sities spanning the country, thereby generating a UK-wide research
and development foundation of international signiﬁcance. All
centres are committed to research in Ethical, Legal and Social As-
pects (ELSA) of their work, with embedded Responsible Research
and Innovation (RRI) goals and dedicated staff who link the centres,
share experience and develop best practice. This dynamic envi-
ronment for research and training brings together a critical mass of
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tion sector to make their own signiﬁcant investments in synthetic
biology, and attracting substantial additional funding from industry
and from international grants and partnerships.
Although the centres were selected ﬁrst and foremost on the
basis of individual excellence, the net outcome has been to generate
a national research infrastructure that has a broad geographical
footprint and spread of academic and potentially commercial in-
terests. Critical mass of facilities and researchers is achieved at both
national and regional scales. The primary focus of each centre is
summarized as follows, but there are also many examples of
collaborative activities between different centres, drawing upon
the broad base of resources and expertise available throughout the
national network. Each research centre also brings its own set of
international partnerships to the overall enterprise.
CSynBI - the Centre for Synthetic Biology and Innovation at
Imperial College [40] applies a twin track strategy to engineering
biology - the development of platform technologies and applica-
tions. Platform technologies include: information systems, stan-
dards (SBOL and DICOM-SB), detailed protocols for characterisation
(BioParts, devices and chassis) and DNA assembly. Application
areas include: biosensors, biocomputing, production therapeutics,
cell-based therapies, advanced biofuels and biomaterials, penicillin
from yeast and participation in the yeast synthetic genome project
Sc 2.0 [41].
BrisSynBio e the Synthetic Biology Research Centre at the
University of Bristol [42] seeks to improve the ability to design and
engineer biological molecules and systems with a particular focus
on proteins, and to apply this knowledge in applications relevant to
health and UK industry. Application areas include: producing ag-
rochemicals, pharmaceuticals and ﬁne chemicals in bacteria, new
vaccines against dengue fever and other unmet clinical needs,
developing new methods to increase the yield of wheat.
SYNBIOCHEM e the Synthetic Biology Research Centre for
Fine and Speciality Chemicals at the University of Manchester
[43] focuses on the synthetic Biology of ﬁne and speciality chem-
icals production (including new products and intermediates for
drug development, agrochemical and newmaterials for sustainable
bio-manufacturing). Applications are being developed through
active collaborations with a large variety of industry partners to
propel chemicals/natural products production towards ‘green’ and
more sustainable manufacturing processes.
OpenPlant - a collaboration between the University of Cam-
bridge, the John Innes Centre and The Sainsbury Laboratory in
Norwich [44] is accelerating the development of new tools and
methods for plant synthetic biology and facilitating their open
exchange and application of standard tools for trait development.
Application areas include the development of new medicines,
chemicals and green energy sources, including enhanced photo-
synthesis and nitrogen ﬁxation.
SynBio e the Synthetic Biology Research Centre at the Uni-
versity of Nottingham [45] applies synthetic biology to organisms
that can digest materials and convert single-carbon gases intomore
desirable and useful molecules. Applications include the sustain-
able production of chemicals and fuels to reduce reliance on pet-
rochemicals, utilisation of waste greenhouse gases and thereby to
facilitate the emerging waste economy.
The UK Centre for Mammalian Synthetic Biology Research -
at the University of Edinburgh [46] is building expertise in cell
engineering tool generation, whole-cell modeling, computer-
assisted design and construction of DNA and high-throughput
phenotyping to enable synthetic biology in mammalian systems.
Applications include tools and technologies for near-term com-
mercial exploitation by the pharmaceutical and drug testing in-
dustries, diagnostics, novel therapeutics, protein based drugs andregenerative medicine, and participation in the yeast synthetic
genome project Sc 2.0.
WISB e the Warwick Integrative Synthetic Biology Centre
[47] addresses speciﬁc, industrially relevant design challenges
across the scales of biological organisation: genetic circuits, path-
ways, and multi-cellular systems, also providing us with a better
understanding of some of the key mechanistic and evolutionary
principles underpinning living systems. Application areas include
pharmaceuticals, high-value and commodity chemicals, treatments
for disease, environmental bioremediation, and food security.
2.2. Build a skilled, energised and well-funded UK-wide synthetic
biology community
It was recommended that attention should be given to devel-
oping a skilled, energised, responsible and well-funded commu-
nity, involving the stimulation of cross-disciplinary interactions
and sharing of best practice, encouraging innovative research
proposals and facilitating the development of valuable applications.
This, together with the provision of further guidance on responsible
research and innovation and other training initiatives, was aimed at
the establishment of an increasingly secure and conﬁdent ‘can-do’
culture, and also to facilitate increased levels of interaction be-
tween the research community and other stakeholders and publics.
To provide a central access point for any individual interested to
know more about synthetic biology in the UK, and to be able to
engage directly in discussions, an online Synthetic Biology Special
Interest Group (SIG) was formed immediately following the Road-
map publication in 2012 [48]. Membership registrations grew to
over 1000 within the ﬁrst two years, comprising 44% from
academia, 28% from Industry, and 7% public sector, with 26% mixed
or unknown background e demonstrating a broad spectrum of
stakeholder interests and engagement. In addition to providing up
to date information, the SIG provides a mechanism to seek views
from a broad spectrum of interest groups via online questionnaires
which, for example, have been used to review progress and to seek
suggestions for further improvement in the systems we have put in
place to help progress synthetic biology in the UK.
Centre for Doctoral Training (CDT). Another important initia-
tive was to further boost the supply and training of synthetic
biology scientists beyond that already being carried out in existing
and the new research centres, by forming a synthetic biology centre
for doctoral training. Typically in the UK PhD students take three
years to four years to complete their doctoral research under the
supervision of one or more academic advisors within a research
group (or possibility more than one group if the project is multi-
disciplinary in nature). The CDT (otherwise known as a DTC e
Doctoral Training Centre) model involves a wider cohort of stu-
dents, either from one university (or a small number of univer-
sities). In the CDT model students are organised into cohorts
working within a broad common scientiﬁc area. There is, typically,
a lot of student interaction and the CDTmodel also usually involves
a considerable amount of transferable skills training. In practice a
coordinated three-centre structure was established ‘SynBioCDT
[49]’, comprising a collaboration between the universities of Ox-
ford, Bristol and Warwick, offering a rolling series of four-year
doctoral training courses. The third annual cohort of students
from this programme is due to start in the Autumn 2016.
iGEM, the international genetically engineered machine
competition [50], is recognised in the UK as an integral and very
important mechanism for attracting predominantly undergraduate
students from a wide range of background and providing valuable
training, and in working in multi-disciplinary teams in the pro-
duction of biologically-based devices. British teams have been
highly successful in the competition over the years, including a
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signiﬁcant proportion of graduates starting synthetic biology ca-
reers have been inspired by taking part in iGEM and ten companies
have already formed directly from iGEM projects, with four of these
in the UK.
2.3. Invest to accelerate technology responsibly to market
This third recommendation sought to generate an environment
in which commercialisation of a potentially disruptive technology
could ﬂourish, reﬂecting the very early and potentially open-ended
stage of development of the sector at the time the Roadmap was
being generated. Issues to be addressed included mechanisms to
attract investment into a relatively unfamiliar topic area frommany
would-be investors, including building conﬁdence through helping
innovators to apply synthetic biology in a responsible way to create
new products, processes or services.
The concept of Innovation and Knowledge Centres (IKCs) had
already been successfully established in the UK as a mechanism to
nucleate new industries, by closing the gap between scientiﬁc
research and its commercial exploitation. IKCs are a key component
of the UK's approach to the commercialisation of emerging tech-
nologies through creating early stage critical mass in an area of
disruptive technology. It was recommended that an IKC be included
within this overall structure to assist the important function of
academic/business integration in synthetic biology. The UK's IKC for
Synthetic Biology ‘SynbiCITE’ (pronounced synbi-city) was awar-
ded to Imperial College London [51] in 2013, and is one of seven
IKCs set up in the UK to facilitate the development of new
industries.
SynbiCITE e the UK's national industrial centre for synthetic
biology is designed to be an effective industrial translation engine
e bridging the gap between university-based research and indus-
trial processes to create products and jobs, through industry. It
provides a national centre of expertise in technology development
and commercialisation for the beneﬁt of the UK economy - facili-
tating collaboration of UK's leading academic institutions and in-
dustrial partners, ranging from start-ups to large multinational
companies, and supporting organisations including the Northern
Ireland, Scottish and Welsh Regional Governments and the Greater
London Authority. SynbiCITE's extensive network of partners
currently includes 20 U.K. universities and over 50 industrial and
commercial partners, made-up of multinational companies, SMEs
and start-ups.
Working closely with colleagues in the US, SynbiCITE has pio-
neered the development of industrial translation training in syn-
thetic biology in the UK, including the nurturing of entrepreneurs
through the Lean Launchpad programme, and delivering core
business skills through the ‘four-day MBA’ programme. A major
training programme for future leaders is provided via the one-year
synthetic biology Leadership Excellence Accelerator Programme
(SynBioLEAP), a joint programme between Imperial College and
Stanford University, aiming to develop the skills needed to lead
responsible synthetic biology development in a global context.
2.3.1. DNA synthesis foundries
Practical assistance to start-up companies at SynbiCITE is based
around its accelerator facilities, including its DNA synthesis and
construction Foundry [52]. The Imperial College Foundry was
launched in April 2016 [53]. The most recent synthesis centre to be
launched in the UK, in July 2016 [54], is the Edinburgh Genome
Foundry [55] ‘SynthSyS’.
These initiatives bring the total of DNA Synthesis Foundries
recently established in the UK to ﬁve - Edinburgh Genome Foundry,
Liverpool Gene Mill, MRC Laboratory of Molecular Biology, DNASynthesis and Construction Foundry at Imperial College and The
Genome Analysis Centre at Norwich Research Park. The different
foundries have different emphases and designs linked to the main
focus of their associated research e for example, the Imperial
Foundry is industry facing and modular.
Such foundries will facilitate a step change in productivity
because they enable the introduction of extensive automatic,
reducing experimental errors and greatly improving reproduc-
ibility. Also, they allow massively parallel experimentation and
correspondingly faster data generation.
2.3.2. Technical standards
Underpinning the translation of ideas into industrial production
is the need to establish a framework of robust engineering princi-
ples and practices. Core elements of such a framework include the
timely setting of appropriate standards. The development of
internationally recognised standards in synthetic biology was rec-
ognised very early on as key to the industrialisation of biological
‘parts’ and processes, alongside the need for data format standards
required for seamless transfer between laboratories. Biological
‘parts’ are units of biological activity (normally encoded by DNA)
that can be assembled into systems or devices. In recent years the
Flowers Consortium has achieved major progress in developing
information systems, data-mining, CAD standards (SBOL and
DICOM-SB), and modeling - as well as detailed reproducible pro-
cedures for characterisation (BioParts, devices and chassis) and
DNA assembly [56], with joint support from the EPSRC in the UK
and NSF in the US.
The emergence of best practice will be best achieved incre-
mentally, reﬂecting the pace of development and in anticipation of
evolving needs. Innovate UK funded The British Standards Institu-
tion (BSI) [57] in 2015 to produce the ﬁrst guidance on the use of
standards in synthetic biology (PAS 246) [58]. The adoption of SBOL
(synthetic biology open language) standards in 2016 by the journal
ACS Synthetic Biology as the basis for depicting genetic constructs
and as the basis for recording and sharing the designs of engineered
organisms [59] illustrates how such standards can be expected to
steadily impact market practice.
This recommendation directly associates the notion of re-
sponsibility with the acceleration of technology. This is captured
through the introduction of ‘Responsible Research and Innovation’
(RRI) as an essential value system for funders and practitioners
alike. This is regarded as a very important and integral aspect of any
prospective research activity, including synthetic biology, and is
described in more detail in Section 4.4 below.
2.4. Assume a leading international role
Although the UK Roadmap necessarily focused on developing
capabilities and realizing opportunities within the UK, it is fully
recognised that such activities are enabled and enhanced by
progress across the envelope of leading-edge science globally,
especially that being carried out in the US. International collabo-
ration is an essential factor underpinning progress in synthetic
biology, reﬂecting the increasingly knowledge-based and inter-
connected nature of 21st century society. Clear economic beneﬁts
derive from increasing scientiﬁc activity between countries, and
this expectation lies behind a range of initiatives including jointly
funded research programmes in synthetic biology spanning the US
and Europe and China. International research-level agreements and
collaborative working are a characteristic of research at all the
major synthetic biology research centres in the UK.
UK funding council investments into synthetic biology have
helped place the UK in a prime position to continue its interna-
tional role, not only technologically but for example in helping
L.J. Clarke, R.I. Kitney / Synthetic and Systems Biotechnology 1 (2016) 243e257 251establish international standards, both technical and regulatory,
sharing experience in Responsible Research and Innovation, and by
contributing positively towards the overall international response
to global challenges including health and the environment. This is
being achieved through a variety of mechanisms, such as partici-
pating in trans-national grant funding, hosting international con-
ferences and by continuing to foster coordinated efforts in synthetic
biology through research partnerships.
2.5. Establish a leadership council
Due to the wide range of envisaged potential synthetic biology
applications and the corresponding number of institutional bodies
involved in different aspects of synthetic biology reﬂected in the
Roadmap, it was clear that there would need to be a single body
capable of spanning these many interests, to act as a visible and
effective point of co-ordination. It was also recognised that,
whereas the original roadmap had set a clear vision and value
system which should provide the foundations for long-term
development, due to the rapid pace of development, the recom-
mendations for research and commercial translation could only
provide the ﬁrst step of an adaptable, responsive system that would
need ongoing reassessment. Agility and responsiveness must be
built in at the institutional systems level to match the rapid pace of
development and learning of the technology itself. It was therefore
proposed to establish an ad-hoc UK Synthetic Biology Leadership
Council (SBLC), to own and oversee delivery of the vision and
roadmap recommendations, to assess progress and update rec-
ommendations and priorities within the roadmap, as and when
needed.
The UK Synthetic Biology Leadership Council was formed in Nov
2012. As subsequently described in the recommendations of the
2013 Policy document, it was co-chaired by an industrialist and a
member of government, providing a unique balance of council in-
dependence with an effective mechanism to inform the ongoing
development of government policy.
The composition of the leadership council has evolved and will
continue to do so as the main focus of attention shifts over time.
Consistent with the objective of retaining agility and responsive-
ness, the council has been numerically constrained in size, but
supported by the establishment of sub-groups and through
engagement with others as and when needed, to reach out to the
broader community of experts and interest groups. Two subgroups
are of particular importance for the functioning of the leadership
council.
The Governance Subgroup (GSG) provides a dedicated forum to
inﬂuence the development of an agile and supportive policy and
research processes for synthetic biology in the UK. Social awareness
alongside technological expertise is now embedded in training
programmes, through the framework of Responsible Research and
Innovation (RRI) as recommended in the 2012 Roadmap. Outreach
and community engagement are important and integral to the UK
synthetic biology activities at all the research centres, and effective
consideration of RRI has become an essential feature of research
funding.
The Science and Technology subgroup (STSB) was formed to
provide a ﬁrst-tier engagement mechanism between the SBLC and
representatives of each of the new centres. The function and in-
ﬂuence of this group has continued to evolve as the new centres
have become fully operational over the past two years.
3. Progress and achievements
Signiﬁcant progress has been made towards meeting the ob-
jectives of the ﬁve core recommendations of the 2012 UK Roadmap.The UK Government's ‘Synthetic Biology for Growth’ Programme
has made signiﬁcant capital investments in equipment and facil-
ities for foundational research and development from which a
broad range of potential applications and commercial opportunities
are being generated.
As noted in Section 1.30, rapid advances in information tech-
nology and high-throughput analysis and assembly (using auto-
mation to conduct huge numbers of experiments in parallel) are
making it increasingly possible to address biological system func-
tion from a digital rather than analogue perspective. By applying
core design and engineering principles of characterisation, stand-
ardisation and modularisation to biological systems - allied to a
range of innovations in miniaturisation, automation and metrology
- predictability and development speed can be increased and costs
reduced. This frames the core objectives of synthetic biology. Pre-
viously intractable challenges can be readdressed, and the potential
to commercialise useful applications enhanced. By enabling con-
cepts to be translated more rapidly and reliably into commercially
viable processes, the cost of market entry may be reduced,
competitiveness enhanced and the delivery of beneﬁts accelerated.
UK public sector investment has totalled approximately £300 M
in the last eight years and is now attracting increasing amounts of
private investment as start-ups are formed and joint public-private
partnerships are established. Another signiﬁcant metric beyond
funding and investment levels alone is evidence for the dynamic
nature of the ﬁeld. The diversity of background skills and expertise
being assembled in the multi-disciplinary centres, stimulating
entrepreneurship across a wide range of potential applications e
set within a loosely coordinated and broadly inclusive national
framework - has generated a highly effective environment within
which innovation is ﬂourishing. Synthetic biology in the UK is no
longer conﬁned to academic research programmes, but is being
actively translated into commercial opportunities, as the following
examples illustrate.
3.1. Application examples
Scientists at the John Innes Centre in Norwich have discovered a
method to accelerate vaccine production to start within as little as
two weeks from the identiﬁcation of, for example, an inﬂuenza
virus. They applied their research on the little-known plant virus,
cowpea mosaic virus, to produce a non-infective virus-like particle
(VLP) that provides the basis for rapid protein expression in plants
under greenhouse conditions. Commercialised under licence by the
Canadian company Medicago, this technology enabled 10 million
doses of H1N1 swine ﬂu VLP vaccine in just a month, out-
performing the traditional method that would have taken typically
9e12 months. Increasing the speed of response is critical to the
effectiveness of vaccination programmes, enabling them to
accommodate and address the most recent naturally mutated virus
strains as they become known.
The UK company Prokarium is developing vaccines that are
thermostable and can be delivered orally [60]. Increased thermo-
stability e their new vaccine is stable at 4 C for over 3 years - can
be critical to delivering vaccines in places where it is difﬁcult to
maintain the otherwise required cold storage conditions. Using
synthetic biology to generate their Vaxonella® platform, Prokarium
have already brought oral vaccines for Chlamydia trachomatis and
for Clostridium difﬁcile to pre-clinical trial stage. Most recently, it
has received funding from the UK and Mexican governments to
develop three new vaccines against Zika, bacterial diarrhoea and
plague e strengthening response capabilities in the face of
emerging disease threats.
As the old adage goes - prevention is better than cure. Oxitec, a
spin-out from Oxford University UK, has been developing
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of vector-borne diseases such as Dengue-fever, chikungunya and
yellow fever, by suppressing their diffusion by the aedes aegypti
mosquito. This sub-species of mosquito has steadily spread from its
native West Africa to well over 100 countries, alongside increas-
ingly global trade, travel and climate change - the WHO recently
estimated that the aedes aegyptimosquito now lives alongside up to
half the world's population [61]. By modifying the genome of aedes
aegypti mosquito males to render their offspring infertile, the
resulting self-limiting OX315A mosquitos can be released to seek
out andmatewith the local female aedes aegyptimosquitos, rapidly
collapsing populations in the target areas by over 95% without the
need for to use more broadly-impacting insecticides. The potential
value of such an approach has been recently highlighted by the
recent outbreak of Zika virus initially in South and Central America,
spreading to 21 countries by February 2016 [62] and more recently
identiﬁed in Florida. The US Food and Drug Administration's Centre
of Veterinary Medicine (FDA-CVM) recently published a ﬁnal
ﬁnding of no signiﬁcant impact (FONSI) and a ﬁnal environmental
assessment (EA) for an investigational trial of the self-limiting
mosquito in the Florida Keys [63].
Another spin-out from Oxford University, Oxford Biotrans, has
developed process technologies, based on novel designs of the
P450 enzyme, that yield high-value chemical compounds [64].
Their ﬁrst product nookatone, the ﬂavour and scent of grapefruit, is
made by the biotransformation of valencene, the naturally occur-
ring extract from oranges.
Recognising that nookatone is not only a valuable ﬂavouring
ingredient, but apparently also an extremely effective insect re-
pellent [65], these examples illustrate how a number of scientiﬁc
and commercial developments in the UK may be collectively
related to disease control, just one of the many application area
envisaged for synthetic biology.
It should also be noted that each of these examples draws from
many years of legacy research and development. They also reﬂect
an important feature of innovative researche that the technologiesFig. 2. Number of synthetic biology cosubsequently developed may often contribute to addressing fresh
challenges and applications beyond what might have been initially
envisaged. The potential value or limitations of a particular tech-
nology should not be judged solely on the initial application for
which it is developed but rather in terms of its contribution to
knowledge as a whole.
From very limited numbers ten years ago, over 50 synthetic
biology start-ups and more established companies now operate in
the UK. Based on start-up company data compiled by SynBioBeta,
synthetic biology start-ups in the UK are currently second only to
the US in total numbers, and represent more than half the total for
Europe as a whole [66]. This is consistent with our own indepen-
dent assessment of synthetic biology companies in the UK. From
2009 to 2015, the number of synthetic biology companies operating
in the UK has been increasing at an average rate of about 20% year-
on-year, as illustrated in Fig. 2.
A number of these focus primarily on the development of the
tools and techniques that are helping to accelerate progress in
synthetic biology, rather than on the end applications. For example,
Synpromics [67] (developing promoters that can switch genes on
and off in a much more controlled manner than previously
possible), Desktop Genetics [68] (developers of DESKGEN, a soft-
ware system to help scientists design genome editing experi-
ments), Sphere Fluidics [69] (developing micro-ﬂuidic technology
that enable the rapid screening and characterisation of single cells
and their biological products) and Lab Genius [70] (a gene synthesis
company, offering proprietary technology that enables allows the
construction of high complexity libraries).
To highlight just one out of the many, it may be noted that
Synthace (developer of Antha, ‘a high-level programming language
for biology, designed to make simple, reproducible and scalable
workﬂows that are easily automated and shared’) was recently
picked as one of the world Technology Pioneers by the World
Economic Forum (WEF) [71]. Five out of the thirty technology pi-
oneers (early-stage companies) awarded this year are associated
with synthetic biology, reﬂecting the view by the WEF that thempanies in the UK 2008-present.
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society’.4. UK Synthetic Biology Strategic Plan 2016
This faster than originally anticipated rate of application
development and commercialisation within the system stimulated
the Leadership Council to initiate, in 2015, a review of progress,
initiating a Roadmap refresh exercise giving greater focus on
translation and industrialisation aspects than feasible during the
original Roadmap exercise 2011e2012. The SBLC engaged with a
cross section of UK synthetic biology stakeholders to garner their
thoughts on how best to refresh the UK Roadmap for Synthetic
Biology. During summer 2015, workshops were held in Edinburgh,
Birmingham and London. Further input was encouraged through an
online survey and the SBLC discussed their ideas with delegates at
their annual open meeting.
Automating the core build-test-analyse cycle, combined with
development and adoption of ‘higher-level’ languages to instruct
the required operations, is making it possible to focus more on the
intended outcomes than on the mechanics of the underlying build-
test-analyse processes themselves. At its core, synthetic biology
may be reframed as the facilitating toolbox that transforms possi-
bilities into practical options. Reﬂecting our working deﬁnition -
‘synthetic biology is the design and engineering of biologically
based parts, novel devices and systems as well as the redesign of
existing, natural biological systems’ eand can be summarized in
the equivalent ‘higher-level’ term ‘Biodesign’. ‘Biodesign’ technol-
ogy will become increasingly accessible to a broader range of non-
specialists. Translation becomes the process of focussing on and
delivering desired outcomes. This is now becoming a practical re-
ality for simpler systems whilst remaining a signiﬁcant future
research and development target for more complex systems.
A new UK Synthetic Biology Strategic Plan 2016: ‘Biodesign for
the Bioeconomy’ representing the outcome of the refresh exercise
was launched by George Freeman, MP, co-chair of the SBLC, on 24th
February 2016 [72].
Key to fulﬁlling the UK vision for synthetic biology is main-
taining excellent national agility and responsiveness whilst
adhering fully to our core principles as set out in the original
Roadmap. The new plan complements, not replaces, the original
roadmap, which continues to provide the enduring foundation for
this refreshed focus on translation and commercialisation. It builds
directly upon e reafﬁrming, not replacing - the core principles and
initiatives set out in the original roadmap, seeking to accelerate
commercial translation responsibly towards the delivery of prod-
ucts and services of clear public beneﬁt for many years to come.
The Strategic Plan focuses on ﬁve key areas of related strategic
importance: accelerating industrialisation and commercialisation;
maximising the capability of the innovation pipeline; building an
expert workforce; developing a supportive business environment,
and building value from national and international partnershipsTable 1
UK synthetic biology strategic plan 2016 recommendations.
Recommendations UK Synthetic Biology Strategic Plan 2016
1 - Accelerate industrialisation and commercialisation by promoting investment in, an
bioeconomy
2 - Maximise the capability of the innovation pipeline by continuing to research and d
unlock future opportunities
3 - Build an expert workforce by developing the skills required for biodesign and imp
4 - Develop a supportive business environment by promoting strong and integrated go
and responsible innovation
5 - Build value from national and international partnerships by fully integrating the UK
as partners of choice for international collaboration(Table 1).
The context of each of these recommendations may be sum-
marized as follows.4.1. Accelerate industrialisation and commercialisation by
promoting investment in, and translation of, biodesign technologies
and assets to drive growth in the bioeconomy
The translation of synthetic biology into useful applications is
being carried out within large companies and SMEs, but it is the
rate of formation of start-ups that provides the clearest evidence of
accelerating progress towards commercialisation and support of
the bio-economy. An important strategy for ensuring growing
companies are funded is to concentrate on supporting businesses
through a range of tools such as accelerator schemes, as now
established at the IKC ‘SynbiCITE’ at Imperial College, London. Since
its foundation in 2014, SynbiCITE has supported over 50 startup
ventures ranging from speciality chemicals to mobile medical de-
vices, helped entrepreneurs, de-risked the science and technology
by funding proof of concept (PoC) projects and a development of
prototype (DoP) project, and supported ventures in attracting in-
vestment from public and private sources. The wider network of
Synthetic Biology Research Centres described previously also have
a range of industrial partners with clear application development
targets and interact directly with the IKC as suitable for training and
other translation support.
This recommendation reﬂects and acknowledges progress made
to date but also, noting the UK strength in process engineering
(focussing on the design, operation, control, and optimization of
chemical, physical, and biological processes) emphasises the
continuing need to building links to relevant technology centres
with capital intensive plants of value to synthetic biology, such as
the CPI [73] Industrial Biotechnology (Wilton) and National Bi-
ologics Manufacturing Centre (Darlington) [74] facilities as well as
the Catapult network, applying graduated support mechanisms as
required.
In many areas of industry the use of standardised components
and processes is central to enhancing productivity. Consequently,
the development of new metrology and effective technical stan-
dards is essential. The synthetic biology design cycle, based on the
principles of characterisation, standardisation and modularisation,
is nowwell established. The challenge is to develop techniques and
methodology that can be used across a range of applications. This
requires accurate metrology, with the comprehensive use of auto-
mation (e.g. laboratory robots), interoperability and technical
standards. This also underlines the need for reproducibility - i.e. the
ability to repeat precisely the same biological system design and its
realisation at multiple locations (including BioPart characterisa-
tion), using the same protocols. The use of comprehensive auto-
mation and high throughput (HTP) techniques in the design cycle
helps address the need for accurate reproducibility, and these
technologies are becoming increasingly important for the ﬁeld.d translation of, biodesign technologies and assets to drive growth in the
evelop platform technologies that will improve manufacturing efﬁciencies and
lementing them through education and training
vernance, a proportionate regulatory system, excellent stakeholder relationships
synthetic biology community to position UK research, industry and policy makers
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synthetic biology was recognised very early on as key to the
industrialisation of biological ‘parts’ and processes. Biological
‘parts’ are units of biological activity - normally encoded by DNA -
that can be assembled into systems or devices. Internationally
agreed standards for ‘parts’ and the associated metrology materials
remain an important goal now supplemented by a need for data
format standards required for seamless transfer between labora-
tories. These include remote gene assembly and data analysis hubs.
It is suggested that the emergence of best practice will be best
achieved incrementally, reﬂecting the pace of development and in
anticipation of evolving needs. As noted above, Innovate UK funded
BSI to produce the ﬁrst guidance on the use of standards in syn-
thetic biology (PAS 246) [75]. An important goal is to build upon
such initiatives to support effective engagement with global stan-
dard setting agencies, and through multi-national industries, to
facilitate the international development of the ﬁeld.
Underlining the successful development and uptake of synthetic
biology in the UK are government policies that support innovation
and industrymore generally. It was noted in the 2012 Roadmap that
many factors converge favourably to make the UK an excellent
place to progress Synthetic Biology. These remain equally valid
today:
 Healthy ecosystem for new and established businesses (UK
ranked in the top 5% of countries for ‘ease of doing business’ e
deﬁned in terms of business-friendly regulations - by the World
Bank [76])
 Strong academic base in Synthetic Biology, linked to a very
strong innovative culture and heritage across the life sciences,
engineering and physical sciences
 Strong and internationally networked industrial base in appli-
cation areas for synthetic biology
 Agile and responsive funding agencies
 Proportionate and robust regulatory frameworks that are
internationally recognised and well regarded
 Strong UK Government support for the ﬁeld
To these may be added the ‘Patent-Box’ initiative, which pro-
vides a tax break for corporate income earned through the
exploitation of a patented invention, provides a strong incentive to
industries to get more involved in the development of qualifying IP
within the UK. Opportunities to further enhance the operating
environment for innovative businesses in the UK continue to be
explored.
4.2. Maximise the capability of the innovation pipeline by
continuing to research and develop platform technologies that will
improve manufacturing efﬁciencies and unlock future opportunities
This second recommendation reafﬁrms the position adopted in
the original Roadmap, that commercial development derives from a
base of world-class academic science. The development of the
platform technologies that form much of the basis of industrial
translation in synthetic biology beneﬁts from signiﬁcant advances
in related ﬁelds that are also being supported through UK research
investments. It is therefore vitally important that the innovation
pipeline is supported on a continuing basis through investment in
the underpinning science and engineering.
The investments in Synthetic Biology Research Centres noted
previously in addition to the broader range of related research
programmes in academic and industrial groups across the UK pro-
vide an appropriate mechanism to ensure the innovation pipeline
remains supplied with a ﬂow of ideas and options. Although sufﬁ-
cient applications are now ﬂowing from this research base to justifythe current focus on the processes of translation and commerciali-
sation, it must also be recognised that many tough scientiﬁc chal-
lenges remain, for example, when considering eukaryotic
organisms, or the characterising the behaviours of consortia of
microbial communities. A further challenge is the ability to control
intracellular function through the deployment of smart, designed,
biological information and control systems. This will be enabled by
the development of effective, robust biodesign tools that will make
the high level design and implementation of synthetic biology so-
lutions more accessible to a wide range of users.
The development of new chassis will also greatly assist the
implementation and controllability of biodesigns and to improve
manufacturing efﬁciencies. One example of this approach is the
synthetic yeast genome project, Sc2.0, currently ongoing.
Overall, such developments will lead to the more robust and
reproducible solutions required for industrial processes.
4.3. Build an expert workforce by developing the skills required for
biodesign and implementing them through education and training
The original 2012 recommendation was ‘to build a skilled,
energised and well-funded UK-wide synthetic biology community’.
The original goals have been broadly achieved through the for-
mation of the SIG, the formation of the Synthetic Biology CDT, and
the development of a wide range of training courses in the SBRCs,
the IKC and elsewhere.
This new recommendation reafﬁrms the importance of the
availability of an expert workforce in supporting the speed and
development of an emerging area. Historically the emergence of
other “new” scientiﬁc disciplines has often been accompanied by
an ad hoc approach to establishing a trained workforce. It is
important to approach this topic in a more structured manner.
Synthetic biology has always aimed to innovate in awider area than
just the underpinning science, challenging current approaches in
training, innovation and regulation amongst others. Uniquely, from
its inception the discipline has always viewed synthetic biology
training to encompass other essential skills - including entrepre-
neurship, communication and high-level group working. As the
relevant principles become increasingly clear and established,
there is increasing scope to steer relevant training in multidisci-
plinary science, awareness of alternative viewpoints, and the
importance of effective communication between the disciplines not
only in further education, but increasingly throughout the educa-
tion system from higher education to secondary and even to pri-
mary education.
Speciﬁcally relevant to translationand industrialisation is the role
of entrepreneurism. Entrepreneurial skills can signiﬁcantly accel-
erate the realisation of economic beneﬁt from synthetic biology.
Relevant training courses such as the Lean Launchpadprogramme to
develop entrepreneurial skills in postdoctoral researchers has been
established by SynbiCITE. But more entrepreneurial approaches are
now being stimulated at and earlier stage of the education system.
Young scientists are trained in multidisciplinary team working and
commercial awareness through the iGEM competition [77] and
Biotechnology Young Entrepreneurs Scheme (Biotechnology YES).
These and other examples represent signiﬁcant capacity building
and futureUKplans are being aimed atﬁlling gaps and ensuring that
this forward-looking trajectory is maintained.
4.4. Develop a supportive business environment by promoting
strong and integrated governance, a proportionate regulatory
system, excellent stakeholder relationships and responsible
innovation
The application of excellent basic science at industrial scale will
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approach, including government policies, development of stan-
dards, regulatory systems and public and stakeholder engagement
and dialogue. A responsible approach to research and innovation
will be a key component, embedded within that environment.
Responsibility in its broadest sense will be crucial to the successful
delivery of the beneﬁts of synthetic biology.
It was recognised in the original Roadmap, and reafﬁrmed in the
2016 Strategic Plan that it is crucial that this technology continues
to be developed in a socially responsible fashion, and that relevant
stakeholders, regulators and publics be engaged in research and
innovation processes from the outset. Such principles of Respon-
sible Research and Innovation (RRI) are not unique to synthetic
biology, but broadly apply to all emerging technologies. In conse-
quence, applying due consideration of RRI aspects of individual
project proposals has been adopted by funding agencies as an in-
tegral part of the assessment process.
RRI is arguably less about following a formulaic approach to
justifying a particular programme of investigation than about
establishing a critical mindset consistent with the broader value
system developing across the sector. RRI is addressed in all perti-
nent training programmes, including the training for all iGEM
teams, who may represent the mainstream of future researchers
and entrepreneurs in the ﬁeld. Each of the UK SBRCs includes social
scientists assessing RRI issues associated with the activities of each
centre. These RRI groups also form a network across the UK that is
helping inform best practice.
The Governance sub-group of the UK Synthetic Biology Lead-
ership Council provides a central point of contact for relevant issues
to be raised and discussed in more depth than possible by the full
Leadership Council. Issues addressed include linkages to regulatory
processes, public engagement and the development of suitable
standards and guidelines. A feature of the integrated roadmap
process is that relevant issues are being addressed at an early stage
e parallel with ongoing research and development, rather than
sequentially - allowing greater time for engagement and delibera-
tion before speciﬁc ideas evolve into potentially commercial
applications.
4.5. Build value from national and international partnerships by
fully integrating the UK synthetic biology community to position UK
research, industry and policy makers as partners of choice for
international collaboration
Synthetic Biology and closely related technologies are being
pursued across the world, and international collaborations and
partnerships play an important role in its continuing development.
The UK synthetic biology research community is highly networked
with other world-leaders in the ﬁeld and has played host to major
international synthetic biology events such as one of the three ‘six
academies’ US, UK, China meetings in 2011, SB6.0, held at Imperial
College in 2013, and SynBioBeta in 2015 and 2016. The SBLC has
engaged with delegations from several countries to compare pol-
icies and strategies and share best practice.
The geographical spread of rising interest can already be gauged
from the participation of student teams from 30 different countries
in recent iGEM competitions [78], and there is an important and
increasing opportunity to engage and interact more effectively with
research groups in the developing world. A number of early ap-
plications directly address developing world needs, such as the
development of an arsenic biosensor for drinking water [79] and
the development of oral vaccines [80], in addition to the pioneering
example of the anti-malarial, artemisinin. Synthetic biology is
becoming increasingly suited to distributed operations and this
should make it easier not only to develop applications for thedeveloping world, but to co-develop applications through the
merging of local knowledge and expertise with centralised exper-
tise and resources.
Ongoing activities that will help lay the foundations for more
international development include the establishment of standards
and guidelines (as noted under recommendation 1 above), material
transfer agreements and internationally recognised governance
systems.
4.6. Synthetic biology contribution to the bioeconomy
Recognising this new stage of development of the technology in
the UK, increasing attention may now be given to the commercial
applications and channels to market. For the foreseeable future, the
main applications are likely to fall within the scope of existing
business sectors. Within the UK, relevant sectors span the bio-
economy [81]. Combining the expertise and interests of these
sectors through representatives of the Synthetic Biology Leadership
Council, the Industrial Biotechnology Leadership Council, the Agri-
Food-Tech Leadership Forum, a working deﬁnition of the UK Bio-
economy is expressed as [82]:
“All economic activity derived from bio-based products and
processes which contributes to sustainable and resource-efﬁcient
solutions to the challenges we face in food, chemicals, materials,
energy production, health and environmental protection.”
In this context, synthetic biology and emerging biodesign ca-
pabilities can be positioned clearly at the innovative core of the
bioeconomy, providing fresh options and opportunities for
advancement, ranging from incremental to disruptive, across all
these challenge areas.
5. Conclusions
Synthetic biology is capable of delivering new solutions to key
challenges spanning the bioeconomy, both nationally and inter-
nationally. Recognising this signiﬁcant potential and the associated
need to facilitate its translation and commercialisation the UK
government commissioned the production of a national Synthetic
Biology Roadmap in 2011, and subsequently provided crucial sup-
port to assist its implementation.
Critical infrastructural investments have been made, and
important strides made towards the development of an effectively
connected community of practitioners and interest groups. A
number of Synthetic Biology Research Centres, DNA Synthesis
Foundries, a Centre for Doctoral Training, and an Innovation
Knowledge Centre have been established, creating a nationally
distributed and integrated network of complementary facilities and
expertise.
The UK Synthetic Biology Leadership Council responded to the
completion of the initial wave of investments and to the rapid
technological progress being made nationally and internationally
to address the next phase of the Roadmap, via the publication of the
UK Synthetic Biology Strategic Plan, in February 2016. The title
‘Biodesign for the Bioeconomy’ reﬂects the shifting focus towards
translation and commercialisation - the design of applications and
the delivery of beneﬁts. Key recommendations include building a
skilled workforce, reafﬁrming core principles of responsible
research and innovation, and ensuring effective oversight and
governance.
The UK is now well positioned to generate and deliver beneﬁts
from the ﬁeld of synthetic biology, building upon its established
science base and structured approach. Over 50 start-ups, SMEs and
larger companies are actively engaged in synthetic biology in the
UK, and inward investments are starting to ﬂow.
Together these initiatives provide an important foundation for
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research and development partnerships, and helping deliver useful
beneﬁts from synthetic biology in response to local and global
needs and challenges.
Disclaimer
This paper sets out to reﬂect the processes and progress in
synthetic biology throughout the UK to date. The authors have
attempted to provide a fully representative summary, and have
drawn extensively upon the signiﬁcant contributions of others as
expressed in the UK Roadmap 2012 and UK Strategic Plan 2016,
often quoting verbatim from such sources to reﬂect as accurately as
possible the original intentions. Any misinterpretations, omissions
or errors in so doing are entirely the responsibility of the authors.
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